A lexey Repik is a Russian entrepreneur who founded and owns R-Pharm, one of Russia's largest pharmaceutical companies. He started his career in healthcare in the 1990s and founded R-Pharm in 2001. The company began as a distributor of drugs for other manufacturers, but Repik strategically pivoted the business towards manufacturing its own pharmaceuticals.
R-Pharm has become a major producer of a wide range of medicines, including high-tech cancer drugs and, more recently, Covid-19 treatments and vaccines. The company has been a significant beneficiary of the Russian government's import substitution program, which aims to boost domestic production of critical goods, including pharmaceuticals. R-Pharm is a major supplier to the Russian state healthcare system, securing large government contracts that have fueled its rapid growth. Repik has become one of the most influential figures in Russia's pharmaceutical industry.
Advertisement
Alexey Evgenievich Repik, born on August 27, 1979, in Moscow, Russia, is a self-made pharmaceutical billionaire and founder of the R-Pharm group. His path to entrepreneurship began young and was immediately focused on the healthcare sector.
His educational journey was unique: he only formally enrolled in university after his business was established, graduating from the Higher School of Economics (HSE) with a degree in economics in 2002. His entrepreneurial career began at the age of 22, in 2001, when he founded R-Pharm with a startup capital of just '$40,000', with nearly half borrowed from his mother. His first breakthrough came from leveraging his knowledge of English and Western business conduct to approach foreign pharmaceutical companies.
Alexey Repik’s professional life is a story of relentless political and industrial integration. He founded R-Pharm in 2001 as a pharmaceutical distribution company. The company grew rapidly, gaining significant market share by supplying essential medicines to Russia's federal programs. Within four years, R-Pharm had surpassed his previous employer in sales, becoming the dominant business in his life.
His career is marked by securing major state contracts—a crucial factor in his wealth growth, earning him a rank among Forbes' 'Kings of the state order'. He strategically positioned R-Pharm as a vertically integrated international company, investing heavily in R&D, infrastructure (including acquiring a technology center in Bavaria), and securing partnerships with global giants like AstraZeneca (for COVID-19 vaccine production) and Mitsui. His final major strategic move was the sale of his stake in R-Pharm in 2022 to the company's management to protect the firm from international sanctions.
Advertisement
Founded R-Pharm at the age of 22 with $40,000 in startup capital.
Graduated from the Higher School of Economics (HSE).
R-Pharm surpassed his previous employer in sales.
Mitsui acquired a 10% stake in R-Pharm for $200 million.
Elected Chairman of the all-Russian public organization 'Delovaya Rossiya'.
Sold his stake in R-Pharm to management to protect the company from sanctions.
Consolidated 100% ownership of the drug retailer EApteka.
Subject to sanctions by the EU, UK, and US due to his association with the Russian regime.
Alexey Repik’s wealth is generated from his founding of R-Pharm Group and his subsequent activities as a politically connected industrialist and investor.
Advertisement
Alexey Repik has been actively involved in social and philanthropic work for many years, often funding initiatives alongside the Russian Orthodox Church and focusing on entrepreneurship.
His broader civic role is as a 'public ombudsman' and co-chairman of business and industry councils, actively shaping national strategy under the President's Council for Strategic Development.
Advertisement
“We shouldn't be afraid to admit when we aren't yet capable of doing something.”
“The main thing in business, the main thing in work and the main thing in the economy is a team, these are people and they need to be trained, they need to be raised, they need to be motivated, they need to be preserved.”
Advertisement
-0.34% | -$50.35M
-0.14% | -$5.07M
This profile is compiled from verified biographical and financial records:
All information is cross-referenced with public sources for accuracy; some narrative sections are AI-assisted summaries.
If you find any inaccuracies, please report them to admin@redcarpetlife.in
Sponsored Content